Peptides DB
Research-centric peptide and protocol reference hub
Study 41 of 46Orforglipron (LY-3502970) literatureDiabetes, obesity & metabolism · ObservationalHigh-impact journal2025

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).

Individuals with overweight or obesity prefer medications that offer effective weight loss and cardiovascular benefits, particularly those that can be taken orally.

Read at Diabetes, obesity & metabolismAdd to compare

Where it sits

this study against the rest of the orforglipron (ly-3502970) corpus
14
Preclinical
9
Observational · this one
1
Open-label
14
Randomised
8
Reviews

Summary and findings

This study evaluated preferences for obesity medications among US adults with overweight or obesity. Participants completed a discrete-choice experiment comparing hypothetical medication profiles based on various attributes. The findings indicated a strong preference for oral medications over injections.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
84.2% preferred Treatment A vs 15.8% for Treatment B.n=8002025

Abstract

The authors’ words, as Diabetes, obesity & metabolism supplied them

<h4>Aims</h4>To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity.<h4>Materials and methods</h4>US adults with obesity or overweight and ≥ 1 obesity-related complication completed an online survey including a discrete-choice experiment (DCE) in October-November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed-choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random-parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice.<h4>Results</h4>Among 800 participants (400 OM-naïve/400 OM-experienced, 400 injection-naïve/400 injection-experienced), the most important attributes were route of administration, average weight-loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A-a hypothetical oral semaglutide-like profile) over the alternative OM profile (Treatment B-a hypothetical orforglipron-like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed-choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM-naïve participants were open to taking an oral OM.<h4>Conclusions</h4>Individuals with overweight or obesity prioritise weight-loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.

Background

This paper addresses the preferences for obesity medications among individuals with overweight or obesity, a population that often faces challenges in treatment adherence. Prior research has indicated that factors such as efficacy and side effects significantly influence medication choice. Understanding these preferences is crucial for developing effective obesity treatment strategies and improving patient outcomes.

Methods

The study utilized a discrete-choice experiment (DCE) involving 800 US adults with obesity or overweight and at least one obesity-related complication. Participants were divided into groups based on their previous experience with obesity medications. The DCE assessed preferences for various medication attributes, including efficacy, cardiovascular risk reduction, and administration route.

Results

The primary finding indicated that 84.2% of participants preferred Treatment A (hypothetical oral semaglutide-like profile) over Treatment B (hypothetical orforglipron-like profile). The most important attributes influencing preferences were route of administration, average weight-loss percentage, and cardiovascular risk reduction. Dosing instructions were deemed the least important.

Interpretation

These findings align with previous literature emphasizing the importance of efficacy and administration route in medication preferences. The effect size regarding preference for oral administration over injections may be clinically meaningful, as it suggests a potential barrier to treatment adherence. However, the reliance on hypothetical scenarios and self-reported data introduces confounding factors that may limit the generalizability of the results.

Key findings

  • 84.2% preferred Treatment A (hypothetical oral semaglutide-like profile) over Treatment B (hypothetical orforglipron-like profile).
  • 90.0% chose Treatment A over Treatment B in a fixed-choice question.
  • 73.3% of OM-naïve participants were open to taking an oral obesity medication.
  • Only 23.4% indicated that taking an obesity medication on an empty stomach and waiting 30 minutes to eat would be disruptive.

Limitations

  • self-reported preferences may not reflect actual medication adherence
  • hypothetical scenarios may not predict real-world behavior
  • no long-term follow-up to assess actual treatment outcomes

Elsewhere in the Orforglipron (LY-3502970) corpus

ASafety and efficacy of oral non-peptide GLP-1 receptor agonist in non- diabetic obese patients; systematic review and meta-analysis of randomized controlled trialsbiorxiv-preprint · 2026 · MD −7.61% body weight reduction vs placebo, 95% CI −8.59 to −6.62; p<0.0001; I²=74.0%reviewAOrforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).JAMA · 2026 · Mean AHI change was -17.8 for orforglipron vs -4.5 for placebo in trial 1, difference -13.2 [95% CI, -17.7 to -8.7]; P < 0.001 at 52 weeks.HumanDOrforglipron for Obstructive Sleep Apnea: Research Summary.JAMA · 2026reviewAEfficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m(2) and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obesity pillars · 2026 · At Week 72, orforglipron 17.2 mg was associated with a mean percent body weight reduction of -13.5% versus placebo at -0.3%, nominal p < 0.001.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.HumanAOrforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials.Obesity pillars · 2026 · Not reported in abstract.Human